.jpg "Analysts Offer Insights on Healthcare Companies: Spectrum Pharmaceuticals (NASDAQ: SPPI), Eiger Biopharmaceuticals (NASDAQ: EIGR) and Heska Corp (NASDAQ: HSKA)")
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Spectrum Pharmaceuticals (NASDAQ: SPPI), Eiger Biopharmaceuticals (NASDAQ: EIGR) and Heska Corp (NASDAQ: HSKA).
Spectrum Pharmaceuticals (NASDAQ: SPPI)
In a report released yesterday, David Buck from B.Riley FBR reiterated a Buy rating on Spectrum Pharmaceuticals (NASDAQ: SPPI), with a price target of $26. The company’s shares opened today at $20.02.
Buck observed:
“We reiterate our Buy rating and $26 per share target for Spectrum Pharmaceuticals (SPPI) shares following the release of ASCO (American Oncology) abstracts Wednesday, May 16th, AMC. Specifically, we remain impressed with Spectrum’s two late-stage assets, poziotinib and Rolontis, as additional data reinforces our positive outlook on the product candidates. One Spectrum-specific abstract (for Rolontis) and one competitive abstract for Takeda’s TAK-788, a potentially competing drug to Spectrum’s poziotinib, or Pozi, were of note.”
According to TipRanks.com, Buck is a 4-star analyst with an average return of 17.1% and a 78.3% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Supernus Pharmaceuticals, and Amag Pharmaceuticals.
Currently, the analyst consensus on Spectrum Pharmaceuticals is Moderate Buy and the average price target is $29.50, representing a 47.4% upside.
In a report issued on May 4, H.C. Wainwright also reiterated a Buy rating on the stock with a $33 price target.
See today’s analyst top recommended stocks >>
Eiger Biopharmaceuticals (NASDAQ: EIGR)
B.Riley FBR analyst Madhu Kumar reiterated a Buy rating on Eiger Biopharmaceuticals (NASDAQ: EIGR) today and set a price target of $24. The company’s shares opened today at $18, equals to its 52-week high of $18.
Kumar observed:
“BioPharmaceuticals (EIGR) announced the expansion of the license agreement from Merck for lead asset lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS). In light of recently published efficacy for lonafarnib in HGPS, this license expansion could support Eiger’s development of the drug in the condition, with the potential near-term value driver of a rare pediatric disease priority review voucher (PRV). We thus reiterate our EIGR Buy rating and $24 price target.”
According to TipRanks.com, Kumar is a top 100 analyst with an average return of 42.1% and a 63.6% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Clementia Pharmaceuticals Inc.
Currently, the analyst consensus on Eiger Biopharmaceuticals is Strong Buy and the average price target is $32.75, representing an 81.9% upside.
In a report issued on May 11, Oppenheimer also reiterated a Buy rating on the stock with a $26 price target.
Heska Corp (NASDAQ: HSKA)
In a report released today, Kara Anderson from B.Riley FBR maintained a Hold rating on Heska Corp (NASDAQ: HSKA), with a price target of $93. The company’s shares opened today at $103.
Anderson commented:
“We are updating our model and price target following $93 PT) investor day earlier this week. Highlights from the day included a detailed overview of Heska’s winning Reset subscription model and product overview, including new analyzers in urine sediment, automated fecal imaging, and upgraded immunodiagnostics to be launched over the next 18 months. Additionally, Heska provided color on its foray into international markets with preliminary expansion set for Zealand later this year and a more mainstream move into Europe next year, the specific details of which are still being hammered out. However, FY18 guidance may disappoint some who were looking for a coordinated improvement in its revenue outlook to offset anticipated incremental investments this year.”
According to TipRanks.com, Anderson is a 3-star analyst with an average return of 6.6% and a 46.9% success rate. Anderson covers the Services sector, focusing on stocks such as Weight Watchers International, Nutrisystem Inc, and TheStreet.
Heska Corp has an analyst consensus of Moderate Buy, with a price target consensus of $90.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
